Immutep Ltd · ASX:IMM
Immutep — Investor Presentation (November 2022)
30 slides from Immutep's investor presentation, Nov 2, 2022
Slide 1: A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease
For personal use only A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease Corporate Presentation – November 2022 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Forward-Looking Statements
Forward-Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanat
Slide 3: Immutep Overview
Immutep Overview For personal use only Pioneering LAG-3 Portfolio Collaborations with Industry Leaders in Oncology & Autoimmune Disease Immutep is a pure-play LAG-3 clinical-stage company with four product candidates that address significant market opportunities in oncology & autoimmune disease Comp
Slide 4: Immutep LAG-3 Pipeline
Immutep LAG-3 Pipeline For personal use only Program Preclinical Phase I Phase II Late Stage Commercial Rights Metastatic Breast Cancer (Chemo-IO) - AIPAC 1st Line Head and Neck Squamous Cell Carcinoma (IO-IO) - TACTI-003 Eftilagimod Alpha (efti or IMP321) 2nd Line Head and Neck Squamous Cell Carcin
Slide 5: LAG-3: Approved Checkpoint with Unique Characteristics
LAG-3: Approved Checkpoint with Unique Characteristics For personal use only Immune system’s role in controlling cancer has led to regulatory approval of immunotherapies targeting CTLA-4, PD-1, and now LAG-3 checkpoints Cytotoxic T lymphocyte Programmed Cell Death Lymphocyte Activating Antigen-4 (CT
Slide 6: LAG-3 Therapeutics for Oncology
For personal use only LAG-3 Therapeutics for Oncology
Slide 7: Multiple Companies Targeting LAG-3 Inhibition
Multiple Companies Targeting LAG-3 Inhibition For personal use only Company* Program Phase 1 Phase 2 Phase 3 Releasing the Brake on T cells 8 35 4 Received FDA approval Relatlimab in March 2022 Blocking LAG-3 / MHC II interaction increases Favezelimab 1 8 1 cytotoxicity of pre-existing CD8 T cell re
Slide 8: Novel Small Molecule Anti-LAG-3 Collaboration
Novel Small Molecule Anti-LAG-3 Collaboration For personal use only Collaboration established in 2019 combining Immutep’s deep LAG-3 biology experience and expertise of world leading scientists at Cardiff University “We are delighted to collaborate with Immutep on this important project to develop a
Slide 9: First-in-Class Positioning in LAG-3 Oncology Landscape via Efti
First-in-Class Positioning in LAG-3 Oncology Landscape via Efti For personal use only Pushing the Accelerator on the Immune System APC activation with Efti Anti-tumor immune cell activation Eftilagimod alpha (Efti) Efti APC LAG-3 MHC II Dendritic Cells T-cells NK Cells Monocytes Human IgG1 Broad act
Slide 10: Driving Adaptive & Innate Immune Response
Driving Adaptive & Innate Immune Response For personal use only Efti initiates persistent increase and activation of Efti drives sustained increase of cytotoxic circulating APCs including monocytes & dendritic CD8 T cells and Natural Killer cells as well as cells, and drives increase in important bi
Slide 11: Synergies with Chemotherapy & IO Checkpoint Inhibitors
Synergies with Chemotherapy & IO Checkpoint Inhibitors For personal use only Chemotherapy releases Activated APCs via efti Cytotoxic CD8+ T cells & other Efti enhances anti-PD-(L)1 therapies’ cancer antigens through acquire cancer antigens & cells key to immunotherapy ability to enable adaptive immu
Slide 12: Pipeline in a Product with Broad Potential
Pipeline in a Product with Broad Potential For personal use only Anti-PD1/PDL1 mAb clinical trials landscape* Efti Clinical Trials Confirm Broad Combination Potential IO-IO Chemo-IO Combination Combination Triple Chemo-IO-IO Combination Efti + Anti-PD-1 (pembrolizumab) Head & Neck Squamous Cell Carc
Slide 13: Treatment Options in 1L NSCLC Limited by Durability & Tolerability
Treatment Options in 1L NSCLC Limited by Durability & Tolerability For personal use only Low PD-L1 status Unmet need in 1L NSCLC patients have poorer High discontinuation rate as median OS still <24 responses to checkpoint due to toxicity limits DoR months for most treatment of chemo and checkpoint
Slide 14: Phase II Trial Evaluating Efti + Pembro in 1L NSCLC
Phase II Trial Evaluating Efti + Pembro in 1L NSCLC TACTI-002/KEYNOTE-798: 1st Line Non-Small Cell Lung Cancer (Part A) For personal use only TACTI-002: Two ACTive Immunotherapeutics in NSCLC & HNSCC Baseline characteristics for PD-L1 All Comer Trial Part A (N=114) Age, median (range), years 67 (44-
Slide 15: Encouraging Clinical Results; Primary Objective Achieved
Encouraging Clinical Results; Primary Objective Achieved; Strong ORR/PFS Across Entire PD-L1 Spectrum vs Pembrolizumab TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) For personal use only 1 Key Takeaways Overall Response Rate* (ORR) Median Progression Free Survival# #(PFS) (with 95% confidence intervals)
Slide 16: Deep and Durable Responses
Deep and Durable Responses TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) For personal use only Tumor Burden Reduced in Majority of Patients 100 75 baseline baseline 50 from 25 changefrom 0 • Responses are deep & long-lasting; median DoR not yet reached Best%%change -25 -50 • 80% (35) of responses1 alread
Slide 17: Benchmarking against IO & IO-Chemo Combinations
Benchmarking against IO & IO-Chemo Combinations TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) For personal use only Toxicity: TPS Treatment Efficacy(1) AEs leading to disc. Efti + Pembro ORR 45.5% PFS 8.4 mos < 10% ≥ 1% Pembro mono ORR 27.5% PFS 5.4 mos 1-14% Ipi + Nivo(2) ORR 36% PFS 5.1 mos 18% Efti +
Slide 18: PD-X Refractory Patients: Promising Anti-tumor & Safety Data
PD-X Refractory Patients: Promising Anti-tumor & Safety Data TACTI-002/KEYNOTE-798: 2nd Line NSCLC, PD-X Refractory (Part B) For personal use only ORR, PFS and OS for ITT and PD-L1 subgroups Best overall response, ITT PD-L1 TPS ITT <1% 1-49% >50% Tumor response* iRECIST RECIST 1.1 (N=36) (N=13) (N=1
Slide 19: 2L HNSCC: Robust ORR/CR with Long-Lasting Efficacy
2L HNSCC: Robust ORR/CR with Long-Lasting Efficacy TACTI-002/KEYNOTE-798: 2nd Line Head & Neck Squamous Cell Carcinoma (Part C) For personal use only Responses at all PD-L1 levels including 5 iCRs Efti + Keytruda Keytruda Combination* Monotherapy# Best % change from baseline Clinical Trial & Phase P
Slide 20: Fast Track Designation in 1L HNSCC
Fast Track Designation in 1L HNSCC TACTI-003: Phase IIb in 1st Line Head and Neck Squamous Cell Carcinoma (HNSCC) For personal use only Status: • Recruiting (~30% enrolled; recruitment accelerating as further sites have been activated*) • FDA Fast Track designation on strength of TACTI-002 data in 2
Slide 21: Efti + Anti-PD-L1 (Avelumab) in Advanced Solid Tumors
Efti + Anti-PD-L1 (Avelumab) in Advanced Solid Tumors INSIGHT-004: Phase I in Various Advanced Solid Tumors For personal use only Histologically confirmed locally or Stratum D Dose escalation study evaluating efti in combination advanced metastatic Patient eligible to treatment Concurrent avelumab (
Slide 22: AIPAC Phase IIb: Significant OS Improvement Across Multiple Subgroups
AIPAC Phase IIb: Significant OS Improvement Across Multiple Pre-Specified Subgroups with Superior QoL AIPAC: Active Immunotherapy PAClitaxel in HER2–/ HR+ metastatic breast cancer Phase IIb Trial For personal use only AIPAC: Multicenter, placebo-controlled, double-blind, Low Monocytes Luminal B 1:1
Slide 23: Substantial Increase in Monocytes, CXCL10, and Cytotoxic CD8+ T Cells
Substantial Increase in Monocytes, CXCL10, and Cytotoxic CD8+ T Cells Correlated to Stronger OS AIPAC: Active Immunotherapy PAClitaxel in HER2–/ HR+ metastatic breast cancer Phase IIb Trial For personal use only Statistically-Significant Increase Statistically-Significant Correlation: Statistically-
Slide 24: Triple IO-IO-Chemo Combination Trial
Triple IO-IO-Chemo Combination Trial INSIGHT-003: Phase I in Solid Tumors Focusing on NSCLC Adenocarcinomas For personal use only INSIGHT-003 - Third arm (Stratum C) of ongoing Investigator-initiated study focusing on NSCLC adenocarcinomas Triple Combination Approach to Capitalize on Efti’s Synergis
Slide 25: LAG-3 Therapeutics for Autoimmune Disease
For personal use only LAG-3 Therapeutics for Autoimmune Disease
Slide 26: LAG-3: A Key Target in Autoimmune Diseases
LAG-3: A Key Target in Autoimmune Diseases For personal use only Present Approaches Fight the Symptoms of Autoimmune Diseases Treating general inflammation: Corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs Future Approaches Target the Causes of Autoimmune Disease Treating the disease
Slide 27: IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells
IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells For personal use only Deficiency in LAG3 Pathways Linked to IMP761 Immutep’s proprietary humanized IgG4 Development of Autoimmune Diseases (AI) LAG-3–specific antibody A LAG-3–Specific Agonist Antibody for the Treatment of T Cell– Induce
Slide 28: IMP761 Inhibits Inflammatory T Cell Infiltration In Vivo
IMP761 Inhibits Inflammatory T cell Infiltration In Vivo For personal use only IMP761 significantly inhibits T cell infiltration of an antigen-specific intradermal reaction in vivo in an Ag-specific delayed-type hypersensitivity (DTH) model in non-human primate study Inflammatory T cell infiltration
Slide 29: Summary
Summary For personal use only 2022 Milestones Corporate Snapshot • Year to date: • Pioneering LAG-3 portfolio in oncology and autoimmune ✓ 1L NSCLC Oral Presentation at ASCO (TACTI-002; Part A) diseases with four product candidates in multiple clinical trials ✓ 2L NSCLC PD-X refractory data at ELCC
Slide 30: Thank You
For personal use only Thank You